Qihao Guo

Prof. Dr. Qihao Guo

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2016 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
KCKe‐Liang Chen
Ke‐Liang Chen
YXYan Xu
Yan Xu
ACAi‐Qun Chu
Ai‐Qun Chu
DDDing Ding
Ding Ding
XLXiao‐Niu Liang
Xiao‐Niu Liang
QGQihao Guo
Qihao Guo

20 February 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
QZQianhua Zhao
Qianhua Zhao
QGQihao Guo
Qihao Guo
FLFang Li
Fang Li
YZYan Zhou
Yan Zhou
BWBei Wang
Bei Wang
ZHZhen Hong
Zhen Hong
The Trail making test (TMT) is culture-loaded because of reliance on the Latin alphabet, limiting its application in Eastern populations. The Shape Trail Test (STT) has been developed as a new variant. This study is to examine the applicability of the STT in a senile Chinese population and to evaluate its potential advantages and disadvantages. A total of 2470 participants were recruited, including 1151 cognitively normal control (NC), 898 amnestic mild cognitive impairment (aMCI), and 421 mild Alzheimer disease (AD) patients. Besides the STT, the Mini mental state examination and a comprehensive neuropsychological battery involving memory, language, attention, executive function and visuospatial ability were administered to all the participants. In a subgroup of 100 NC and 50 AD patients, both the STT and the Color Trail Test (CTT) were performed. In NC, the time consumed for Part A and B (STT-A and STT-B) significantly correlated with age and negatively correlated with education (p<0.01). STT-A and B significantly differed among the AD, aMCI and NC. The number that successfully connected within one minute in Part B (STT-B-1 min) correlated well with STT-B (r = 0.71, p<0.01) and distinguished well among NC, aMCI and AD. In the receiver operating characteristic curve analysis, the AUCs (area under the curve) for STT-A, STT-B, and STT-B-1min in identifying AD were 0.698, 0.694 and 0.709, respectively. The STT correlated with the CTT, but the time for completion was longer. The TMT is a sensitive test of visual search and sequencing. The STT is a meaningful attempt to develop a “culture-fair” variant of the TMT in addition to the CTT.

7 December 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
QZQianhua Zhao
Qianhua Zhao
YLYingru Lv
Yingru Lv
YZYan Zhou
Yan Zhou
ZHZhen Hong
Zhen Hong
QGQihao Guo
Qihao Guo
Delayed recall of words in a verbal learning test is a sensitive measure for the diagnosis of amnestic mild cognitive impairment (aMCI) and early Alzheimer’s disease (AD). The relative validity of different retention intervals of delayed recall has not been well characterized. Using the Auditory Verbal Learning Test–Huashan version, we compared the differentiating value of short-term delayed recall (AVL-SR, that is, a 3- to 5-minute delay time) and long-term delayed recall (AVL-LR, that is, a 20-minute delay time) in distinguishing patients with aMCI (n = 897) and mild AD (n = 530) from the healthy elderly (n = 1215). In patients with aMCI, the correlation between AVL-SR and AVL-LR was very high (r = 0.94), and the difference between the two indicators was less than 0.5 points. There was no difference between AVL-SR and AVL-LR in the frequency of zero scores. In the receiver operating characteristic curves analysis, although the area under the curve (AUC) of AVL-SR and AVL-LR for diagnosing aMCI was significantly different, the cut-off scores of the two indicators were identical. In the subgroup of ages 80 to 89, the AUC of the two indicators showed no significant difference. Therefore, we concluded that AVL-SR could substitute for AVL-LR in identifying aMCI, especially for the oldest patients.

15 January 2013 in Neuroscience Bulletin
Verified
Journal Article
Closed access
PDF file
QZQianhua Zhao
Qianhua Zhao
QGQihao Guo
Qihao Guo
ZHZhen Hong
Zhen Hong

27 December 2018 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
KDKai-Xin Dou
Kai-Xin Dou
MTMeng-Shan Tan
Meng-Shan Tan
CTChen-Chen Tan
Chen-Chen Tan
XCXi-Peng Cao
Xi-Peng Cao
XHXiao-He Hou
Xiao-He Hou
JYJintai Yu
Jintai Yu
Cholinesterase inhibitors and memantine have been approved for management of Alzheimer’s disease (AD), but there has been no consensus about the choice of various types and doses of drugs at different stages. Hence, we compared and ranked the efficacy and tolerability of these available drugs. We searched PubMed, the Cochrane Central Register of Controlled Trials, and Embase for randomized controlled trials (RCTs) published from database inception to July 21, 2017. The primary outcomes were the mean overall changes in cognitive function and responders who had any adverse events. We conducted a random-effects network meta-analysis. Forty-one RCTs were included in this study. Compared with placebo, galantamine 32 mg daily (standardized mean difference – 0.51, 95% credible interval – 0.67 to − 0.35), galantamine 24 mg daily (− 0.50, − 0.61 to − 0.40), and donepezil 10 mg daily (− 0.40, − 0.51 to − 0.29) were probably the most effective agents on cognition for mild to moderate AD, and memantine 20 mg combined with donepezil 10 mg (0.76, 0.39 to 1.11) was recommended for moderate to severe patients. Memantine showed the best profile of acceptability. Rivastigmine transdermal 15-cm2 patch was the best optional treatment both in function and global changes. None of the medicines was likely to improve neuropsychiatric symptoms through this analysis. Pharmacological interventions have beneficial effects on cognition, function, and global changes, but not on neuropsychiatric symptoms, through current network meta-analysis. The choice of drugs may mainly depend on the disease severity and clinical symptoms.

17 July 2015 in Current Alzheimer Research
Verified
Journal Article
Closed access
PDF file
QZQianhua Zhao
Qianhua Zhao
QGQihao Guo
Qihao Guo
XLXiaoniu Liang
Xiaoniu Liang
MCMeirong Chen
Meirong Chen
YZYan Zhou
Yan Zhou
ZHZhen Hong
Zhen Hong
Objective: To carry out meaningful comparisons on results of different research studies on mild cognitive impairment (MCI), it is critical to select an appropriate objective memory test to examine memory deficit. We aim to refine the operational criteria of amnestic MCI (aMCI) on neuropsychological tests that optimally balance the sensitivity and specificity. Methods: We focused on 206 non-demented subjects from memory clinic. We then classified each individual as having MCI or subjective cognitive decline (SCD) according to different neuropsychological criteria. By following them longitudinally, clinical outcomes were compared to evaluate the stability of MCI diagnoses and prediction of progression. Results: The delayed recall of auditory verbal learning test (AVLT_DR) identified 116 subjects as MCI, resulted in the conversion rate as 44% over the roughly 30-month time interval, missed 7.8% incipient Alzheimer’s disease (AD) patients in SCD group who eventually converted to dementia. The delayed recall of complex figure test (CFT_DR) identified fewer MCI patients (n=95) and misdiagnosed more preclinical AD patients (15.3%), in comparison with AVLT criterion. Criterion requiring deficits in both tests produced higher conversion rate (54.3%), but resulted in higher misdiagnosis rate (14.7%) simultaneously. The AVLT criterion had the largest area under the curve (0.7248, p<0.05). Conclusion: AVLT is superior to CFT in the stability of diagnoses and prediction of progression. In the clinical setting, the “one test” criterion AVLT has similar sensitivity to both-deficits methods, and is optimal in balancing sensitivity and specificity.